News

Results of the phase II clinical study of R112 showed the treatment to be no more effective than placebo in reducing hay fever symptoms. The investigation compared Rigel’s

The QR-441 impregnated masks prevented up to 99% of the viruses whereas the masks not treated with the compound only had the ability to prevent up to 90%

The trial is designed to evaluate the safety and preliminary efficacy of Provecta in five patients with recurrent breast carcinoma. Each patient enrolled in the study is having

The three patients in the multiple sclerosis (MS) trial developed severe idiopathic thrombocytopenic purpura (ITP). One of these individuals died from an intracranial hemorrhage, and dosing with Campath

Akathisia, or quivering of the muscles, is a debilitating side effect often experienced by patients with schizophrenia who are prescribed such antipsychotics. This study is one of two

Under the terms of the agreement, 4AZA will grant to Gilead an exclusive, worldwide license for the research, development and commercialization of certain novel compounds for the potential

Conor received conditional investigational device exemption approval from the FDA to begin the trial in a limited number of sites in March 2005. The first patient was enrolled

This acceptance, which caused the company’s shares to jump by almost 10%, confirms that the application was sufficiently complete to allow a substantive review by the FDA. The

Par is the first generic company to receive a tentative approval for the cabergoline tablets and expects to launch the product following expiration of Pfizer’s US patent on